CoChat

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

Open access
Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Yu, Yerong, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Pedroncelli, Alberto M, Snyder, Peter J · 2022 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Context: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. Objective: We aimed to evaluate the safety and efficacy of osilodrostat, a potent, orally available 11βhydroxylase inhibitor, compared with placebo in patients with Cushing disease. Methods: LINC 4 was a phase III, multicenter trial comprising an initial 12-week, randomized, double-blind, placebo-controlled (osilodrostat:placebo, 2:1) period followed by a 36-week, open-label treatment period (NCT02697734). Adult patients (aged 18-75 years) with confirmed Cushing disease and mean urinary free cortisol (mUFC) excretion ≥ 1.3 times the upper limit of normal (ULN) were eligible. The primary endpoint was the proportion of randomized patients with mUFC ≤ ULN at week 12. The key secondary endpoint was the proportion achieving mUFC ≤ ULN at week 36 (after 24 weeks’ open-label osilodrostat). Results: Seventy-three patients (median age, 39 years [range, 19-67]; mean/median mUFC, 3.1 × ULN/2.5 × ULN) received randomized treatment with osilodrostat (n = 48) or placebo (n = 25). At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001). Response was maintained at week 36, when 81% (95% CI 69.9, 89.1) of all patients achieved mUFC ≤ ULN. The most common adverse events during the placebo-controlled period (osilodrostat vs placebo) were decreased appetite (37.5% vs 16.0%), arthralgia (35.4% vs 8.0%), and nausea (31.3% vs 12.0%). Conclusion: Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgac178

Cites

19 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (A) Study design and dosing schedule and (B) timing of study visits, 24-hour UFC collection, and dose adjustments during the LINC 4 study. Three urine samples drawn at 24-hour intervals were collected by patients at screening, within 7 days prior to day 1, and immediately prior to the week 12 visit (primary endpoint). Two 24-hour urine samples were collected immediately prior to each of the other visits (ie, at weeks 2, 5, and 8). Dose matching and adjustments were managed by independent endocrinologists. *Dose adjustments to normalize mUFC or to address safety concerns were permitted. Dose-titration sequence: 2 mg twice daily →5 mg twice daily →10 mg twice daily →20 mg twice daily (maximum dose in double-blind period) →30 mg twice daily (maximum dose in open-label period). Doses of < 2 mg twice daily (1 mg twice daily, 1 mg every day, 1 mg every other day) were allowed if necessary; †All patients on doses of ≥ 2 mg twice daily started open-label osilodrostat 2 mg twice daily at week 12, while patients on < 2 mg twice daily continued with their most recent dose. Abbreviations: bid, twice daily; IE, independent endocrinologist; mUFC, mean urinary free cortisol; qd, every day; qod, every other day.
Figure 1. (A) Study design and dosing schedule and (B) timing of study visits, 24-hour UFC collection, and dose adjustments during the LINC 4 study. Three urine samples drawn at 24-hour intervals were collected by patients at screening, within 7 days prior to day 1, and immediately prior to the week 12 visit (primary endpoint). Two 24-hour urine samples were collected immediately prior to each of the other visits (ie, at weeks 2, 5, and 8). Dose matching and adjustments were managed by independent endocrinologists. *Dose adjustments to normalize mUFC or to address safety concerns were permitted. Dose-titration sequence: 2 mg twice daily →5 mg twice daily →10 mg twice daily →20 mg twice daily (maximum dose in double-blind period) →30 mg twice daily (maximum dose in open-label period). Doses of < 2 mg twice daily (1 mg twice daily, 1 mg every day, 1 mg every other day) were allowed if necessary; †All patients on doses of ≥ 2 mg twice daily started open-label osilodrostat 2 mg twice daily at week 12, while patients on < 2 mg twice daily continued with their most recent dose. Abbreviations: bid, twice daily; IE, independent endocrinologist; mUFC, mean urinary free cortisol; qd, every day; qod, every other day.CC BY-NC-ND · PubMed Central
Figure 2. Patient disposition flow chart. *Patient was randomly allocated to osilodrostat but did not receive any study treatment because of a serious AE (grade 4 pituitary apoplexy that required hospitalization prior to receiving any study drug) that was not considered related to treatment. Abbreviation: AE, adverse event.
Figure 2. Patient disposition flow chart. *Patient was randomly allocated to osilodrostat but did not receive any study treatment because of a serious AE (grade 4 pituitary apoplexy that required hospitalization prior to receiving any study drug) that was not considered related to treatment. Abbreviation: AE, adverse event.CC BY-NC-ND · PubMed Central
Figure 3. (A) Intrapatient changes in mUFC from baseline to week 12 and (B) proportion of randomized patients with mUFC ≤ ULN up to week 12. ULN for mUFC is 138 nmol/24 hours (50 μg/24 hours). For panel A, each vertical set of data points represents 1 patient and is shown in order of decreasing baseline mUFC. Six patients randomized to osilodrostat and 4 patients randomized to placebo had mUFC ≤ 1.3 × ULN at baseline; however, mUFC was > 1.3 × ULN at screening (ie, patients met the eligibility criterion). Abbreviations: mUFC, mean urinary free cortisol; ULN, upper limit of normal.
Figure 3. (A) Intrapatient changes in mUFC from baseline to week 12 and (B) proportion of randomized patients with mUFC ≤ ULN up to week 12. ULN for mUFC is 138 nmol/24 hours (50 μg/24 hours). For panel A, each vertical set of data points represents 1 patient and is shown in order of decreasing baseline mUFC. Six patients randomized to osilodrostat and 4 patients randomized to placebo had mUFC ≤ 1.3 × ULN at baseline; however, mUFC was > 1.3 × ULN at screening (ie, patients met the eligibility criterion). Abbreviations: mUFC, mean urinary free cortisol; ULN, upper limit of normal.CC BY-NC-ND · PubMed Central
Figure 4. Mean mUFC at time points up to weeks 12 and 48 by randomized treatment group. Dashed horizontal line indicates ULN for mUFC: 138 nmol/24 hours (50 μg/24 hours). Abbreviations: mUFC, mean urinary free cortisol; ULN, upper limit of normal.
Figure 4. Mean mUFC at time points up to weeks 12 and 48 by randomized treatment group. Dashed horizontal line indicates ULN for mUFC: 138 nmol/24 hours (50 μg/24 hours). Abbreviations: mUFC, mean urinary free cortisol; ULN, upper limit of normal.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Nieman, 2021, Metyrapone treatment in endogenous Cushing’s syndrome, abst OC3.3

Cited by

See all 115

Metadata

Authors
Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., Ku, C. H. C., Carvalho, D., Roughton, M., Wojna, J., Pedroncelli, A. M., & Snyder, P. J.
Affiliations
  • Universidade Federal do Rio de Janeiro (BR)
  • Universitair Ziekenhuis Leuven (BE)
  • Erasmus MC (NL)
  • University of California, Los Angeles (US)
  • University of Michigan (US)
  • Department of Endocrinology, Jagiellonian University Medical College , Kraków , Poland
  • Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw , Warsaw , Poland
  • Endocrinology Research Center (RU)
  • West China Hospital of Sichuan University (CN)
  • Sun Yat-sen University (CN)
  • Clinica Los Yoses , San Pedro , Costa Rica
  • Universidade do Porto (PT)
  • Novartis (Switzerland) (CH)
  • Novartis (United States) (US)
  • Recordati AG , Basel , Switzerland
  • University of Pennsylvania (US)
Corresponding author
Gadelha, Mônica
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2022-03-23
Volume
107
Issue
7
Pages
e2882-e2895
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4220667260
Cited by
114
References
19
Citations by year
2026: 24 · 2025: 38 · 2024: 18 · 2023: 22 · 2022: 12
FWCI
16.87
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc-nd)
Funders
  • Eli Lilly and Company
  • Pfizer
  • Neurocrine Biosciences
  • Quest Diagnostics
  • Recordati Rare Diseases
  • Novo Nordisk
  • H. Lundbeck A/S
  • Ipsen
  • Novartis Pharma
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
Cushing's disease, osilodrostat, 11β-hydroxylase inhibitor, hypercortisolism, cortisol suppression, urinary free cortisol, drug safety, adverse events, open-label extension, treatment efficacy, joint pain, appetite loss, nausea
MeSH terms
Adult, Double-Blind Method, Humans, Hydrocortisone, Imidazoles, Pyridines, Treatment Outcome, Pituitary ACTH Hypersecretion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. https://app.cochat.ai/papers/10.1210/clinem/dgac178
The paper
Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., Ku, C. H. C., Carvalho, D., Roughton, M., Wojna, J., Pedroncelli, A. M., & Snyder, P. J. (2022). Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac178

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.